Tag Archives: euglycemic DKA

SGLT inhibitors have changed the treatment landscape for cardiovascular and kidney disease, particularly in people with type 2 diabetes, heart failure, and chronic kidney disease. That success raises an obvious question: why are SGLT inhibitors in type 1 diabetes still largely outside routine clinical practice? The answer is not a …

Euglycemic diabetic ketoacidosis can challenge one of the most familiar clinical shortcuts in diabetes care: DKA should come with markedly elevated glucose. In patients taking sodium-glucose cotransporter 2 (SGLT2) inhibitors, however, dangerous ketoacidosis may develop while glucose remains normal or only modestly elevated. As a result, euglycemic DKA in patients …

New advances in diabetes technology are moving beyond glucose alone. While continuous glucose monitoring transformed diabetes management over the last decade, wearable ketone monitoring systems are now emerging as the next major innovation. Researchers, device manufacturers, and international diabetes organizations are increasingly focused on whether real-time ketone data can help …